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The legend for Fig. 7 contained errors regarding the schedule of treatments administered. Fig. 7 and the corrected legend appear below.
Figure 7.  -GalCer/DC/IL-21 combination mediates extremely 
potent suppression of tumor metastases. Groups of five C57BL/6 WT 
mice were injected i.v. with 5   105 B16F10 tumor cells. Mice were 
treated: (A and C) on day 4 i.v. with 5   105  -GalCer–pulsed DC ( ) or 
vehicle-pulsed DC ( ) and on day 7 i.v. with 20  g of either pORF or 
pIL21 DNA plasmid as indicated; and (B and D) on day 8 i.v. with 5   105 
 -GalCer–pulsed DC ( ) or vehicle-pulsed DC ( ) and on day 11 i.v. 
with 20  g of either pORF or pIL21 DNA plasmid; and (E) on day 8 i.v. 
with 5   105  -GalCer–pulsed DC ( ) or vehicle pulsed DC ( ) and on 
day 11, 12, and 13 with 50  g of recombinant mouse IL-21 or PBS as in-
dicated. In some experiments (A, B, and E) 14 d after tumor inoculation 
the lungs of these mice were harvested and tumor colonies counted and 
recorded as the mean number of colonies   SEM. Asterisks indicate the 
groups where combined  -GalCer/DC/IL-21 treatment significantly re-
duced that group’s number of lung metastases compared with all other 
groups (Kruskal-Wallis: *P   0.05). In other experiments (C and D) the 
survival of these mice was monitored and recorded as the mean survival 
time (days)   SEM. Asterisks indicate the groups where combined
 -GalCer/DC/pIL21 treatment significantly increased that group’s sur-
vival compared with all other groups (Kruskal-Wallis: *P   0.05). Results 
are representative of two experiments performed.
 
CORRECTION